Introduction
============

Arterial hypertension is a systemic disorder characterized by altered regulation of cardiovascular hemodynamics including arterial vascular resistance and cardiac index leading in effect to increase in arterial blood pressure. Whether the hypertension is of the essential type, without obvious underlying disease, or secondary arterial hypertension due to primary causes, such as renal, vascular, metabolic, endocrine, or other disorders, chronically elevated blood pressure is regarded as an established risk factor for the development of cardiovascular disease, such as stroke, chronic ischemic heart disease, myocardial infarction and heart failure. Therefore, arterial hypertension should be the target of vigorous treatment attempts both in primary and secondary preventive medicine ([@b48]).

At first sight, erectile dysfunction (ED) seems to be a field quite different from cardiovascular medicine. However, a closer look demonstrates that it is strongly associated with arterial hypertension and also several other cardiovascular risk factors. Many cases of ED are characterized as "vascular", referring to their strong statistical association with cardiovascular risk factors and cardiovascular events (Virag et al 1995; [@b70]). Among others, hypertension is a cardiovascular risk factor which is significantly associated with ED ([@b2]; [@b35]). In the Massachusetts Male Aging Study the annual incidence of ED in a population of 40--69 year old men amounted to 26 new cases per 1000 men. While the incidence in absolute numbers progressively increased with age, hypertension and also diabetes mellitus and heart disease were significantly associated with ED in every age group ([@b20]; [@b30]). A systematic evaluation of atherogenic risk factors among men with ED reported a prevalence of 44% for hypertension, 79% for obesity, 74% for elevated low-density lipoprotein cholesterol (above 120 mg/dL), 23% for diabetes mellitus, and 16% for smoking ([@b80]). As recently demonstrated, this strong association between the presence of ED and cardiovascular risk factors results in a significantly increased incidence of cardiovascular events among patients with ED ([@b5]). A retrospective analysis of the placebo group from the Prostate Cancer Prevention Trial estimated an 11% 5-year risk of cardiovascular events in patients suffering from ED, which in current terminology of preventive medicine means that ED can be regarded as a "coronary risk equivalent" ([@b77]).

The following paragraphs will discuss some basic aspects of this interrelation between hypertension and ED with respect to similarities in pathophysiology and potential interaction of medical treatment options of the two diseases.

Erectile dysfunction: warning for cardiovascular risk factors and cardiovascular disease
========================================================================================

Endothelial dysfunction: common denominator of atherogenic risk factors and erectile dysfunction
------------------------------------------------------------------------------------------------

[Table 1](#tbl1){ref-type="table"} presents a list of potential causes and factors associated with ED, which should be considered in the patient\'s work-up. Some of them are related to underlying urological, psychosocial or endocrine disorders. However, it is clear that factors associated with the cardiovascular system appear to play a predominant role ([Table 1](#tbl1){ref-type="table"}).

###### 

Risk factors, conditions, and diseases associated with erectile dysfunction

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Risk factor associated with atherosclerosis:**
   SmokingDiabetes mellitusHypertensionlow levels of HDL cholesterol/high levels of LDL cholesterol/high level of total cholesterolsedentary lifestylefamily history of atherosclerosisobesity
  **Neurological factors**
   neuropathy (diabetic, etc)spinal cord injury, cerebrovascular insult, multiple sclerosis, nerve damage due to prostate surgery etc.
  **Medical diseases**
   renal failure,dialysis,abnormal liver function,endocrine disorders (hypogonadism, hyperprolactenemia, hypo- and hyperthyroidism),sickle cell anemia
  **Drugs**
   antihypertensives, thiazide diuretics, spironolactone, digoxin, antidepressants, β-blockers, centrally acting antihypertensives, phenothiazines, carbamazepin, phenytoin, risperidone, fibrates, statins, Histamine-2-receptor antagonists, allopurinol, indomethacin, tranquilizer, disulfiram, levodopa, chemotherapeutics, etc. alcohol, others
  **Others**
   Peyroni\'s disease, priapism, trauma
  **Psychosocial causes**
   depression, anxiety disorder, problems or changes in relationship
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Compiled according to [@b7]; [@b57]; [@b3]; [@b23]; [@b32]; [@b34]; [@b37]; [@b45]; [@b49]; [@b59]; [@b50]; [@b56]; [@b58], and [@b68].

The endothelium, ie, the inner layer of cells that line the vascular network, contributes significantly to vasomotor regulation, via release of nitric oxide (NO), which is a potent vasodilator. Endothelial dysfunction is defined as a reduced vasodilation or even paradoxic vasoconstriction in response to endothelium-dependent vasodilatory stimuli. In many circumstances endothelial dysfunction precedes morphological changes of the vessel wall or the formation of atherosclerotic plaques. In particular, hypertension might be associated with endothelial dysfunction as shear stress within the vessel wall, hypertension, and associated conditions seem to affect endothelial function significantly ([@b47]; [@b53]; [@b75]; [@b54]; [@b11]).

In many patients with ED, inadequate release of NO from nerve endings and endothelial cells or altered response of penile vascular smooth muscle cells to NO appears to be an important step in the pathophysiology of ED ([@b4]). ED, in this context, can be regarded as one manifestation of a generalized process of vascular deterioration. A recent study examined endothelium-dependent and endothelium-independent vasodilation of the brachial artery in men with ED, but without other clinically overt cardiovascular disease ([@b31]). Vasodilation of the brachial artery by both mechanisms was significantly compromised in the group suffering from ED, which illustrates that vascular alterations involved in ED are a generalized process.

Phosphodiesterase 5 inhibitors, namely sildenafil, vardenafil, and tadalafil, which are currently considered to be the most effective medical treatment options for ED, intervene in this pathway of vascular dysfunction ([@b63]): When NO stimulation increases activity of the enzyme guanylate cyclase, intracellular cGMP levels are increased. This mechanism might be further amplified and prolonged in duration by inhibition of the enzyme phosphodiesterase 5, which is responsible for the breakdown of cGMP. Thereby, inadequate vasodilation of the penile arteries in ED as a result of insufficient release of NO can be compensated for by phosphodiesterase 5 inhibition ([@b24]; [@b25]; [@b64], b).

Cardiovascular work-up for the patient presenting with erectile dysfunction
---------------------------------------------------------------------------

Patients without obvious causes for ED, such as anatomical disorders, neurological disease or endocrine causes should be evaluated for cardiovascular risk factors, arterial hypertension, and vascular or arterial disease ([@b34]; [@b33]; [@b71]; [@b72]). The relatively high probability of detecting potentially serious diseases warrants further investigations ([@b22]; [@b64], b).

In addition, the strong association between cardiovascular risk factors and ED should be brought to the patient\'s attention, as this, in some patients, might be a more convincing motivation to modify these risk factors, change lifestyle, effectively treat hypertension, quit smoking, and others, than the sometimes more abstract statistical association between cardiovascular disease and risk factors.

In general, we propose the following medical work-up for a patient presenting with ED with reasonable modification depending on the individual condition. The patient needs to supply a detailed medical history including sexual and psychosocial history along with a complete list of current and previous medication. A cardiovascular examination including peripheral pulses, signs of peripheral ischemia, and others is necessary. To assess the individual risk for cardiovascular diseases, repeated measurement of blood pressure, a fasting blood glucose level, analysis of cholesterol (total, low-density lipoproteins and high-density lipoproteins), body-mass index (according to weight and height), assessment of lifestyle, actual level of physical activity, and potential genetic predisposition should be obtained. A resting electrocardiogram should also be documented. If a patient has three or more atherogenic risk factors an exercise electrocardiogram should be considered as per the Princeton Consensus Panel. In some high risk patients a Doppler-sonographic examination of the carotid arteries and lower extremity arteries might also be included into the work-up.

Patients with diabetes suffering from ED are at special risk for silent cardiovascular disease ([@b22]). Therefore, some authors recommend an exercise test for every diabetic patient presenting with ED, as a significant number of patients with silent ischemic heart disease will be detected ([@b74]).

If the results suggest an increased risk for cardiovascular disease, a referral to a cardiologist is reasonable for detailed diagnostic testing and initiation of therapy. Importantly, the cardiac situation should be carefully clarified before initiation of medical treatment, as phosphodiesterase 5 inhibitors must not be used in certain cardiovascular conditions or at least require special precaution (see below). In addition, detailed recommendations for cardiovascular patients, concerned about a potential risk of sexual intercourse in the light of their underlying cardiovascular condition, are available both for further diagnostic work up and therapeutic interventions according to the first and second Princeton Consensus Conference ([@b15]; [@b43]). Patients are categorized as low-risk, high risk, or, if stabilization or further diagnostics are necessary, as indeterminate or intermediate risk ([Table 2](#tbl2){ref-type="table"}). In the high-risk group, sexual activity should be deferred until a patient\'s cardiac condition has been stabilized by medical treatment, revascularization procedures or by simply waiting until stabilization has occurred. In the intermediate group, further work-up is required, which in many circumstances needs referral to a cardiologist.

###### 

Three risk groups of patients with cardiovascular disease according to the "Second Princeton Consensus Panel" ([@b43]; see also [@b15])

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. Low risk group**
  Patients with
   Two or less atherogenic risk factors, asymtomaticMedically controlled hypertension with ≥1 antihypertensive drugmild, stable angina (consider exercise test in some cases)after successful coronary revascularization (without remaining ischemia)after uncomplicated myocardial infarction (\>6--8 weeks)mild valvular diseaseLeft ventricular dysfunction: New York Heart Association I
  **2. Intermediate or indetermined risk group**
  Patients with
   Three or more atherogenic risk factors, asymptomaticmoderate, stable anginamyocardial infarction (2--6 weeks after the acute event)congestive heart failure: New York Heart Association IInon-cardiac sequelae of atherosclerotic disease (stroke, transient ischemic attack, peripheral vascular disease)
  **3. High risk group**
  Patients with
   unstable angina/refractory anginauntreated, poorly controlled, accelerated, or malignant hypertensioncongestive heart failure (New York Heart Association III--IV)myocardial infarction (within the last 2 weeks)recent strokemoderate to severe valvular heart disease, particularly aortic stenosis or hypertrophic obstructive cardiomyopathyhigh risk arrhythmia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients whose blood pressure is well controlled with one or more antihypertensive drugs are categorized as belonging to the "low-risk group", meaning that sexual activity and also treatment for ED could be safely recommended. However, patients with poorly controlled hypertension, or hypertension before initiation of adequate treatment or malignant hypertension are categorized as "high-risk" for cardiac or vascular events, especially also for stroke ([@b43]). As a consequence these patients first require medical treatment of hypertension and also a diagnostic work-up of accompanying medical disorders.

Sex: a risk for a cardiovascular patient?
=========================================

Among patients and doctors there is substantial uncertainty as to whether sexual activity in different cardiovascular conditions and stages of heart disease can be safely recommended. A cardiovascular patient asking for treatment options for ED, who might have not been sexually active for a certain period of time, needs a realistic, individual estimate of a potential risk of a cardiac event related to sexual intercourse preferentially based on recommendations of the (first and second) Princeton Consensus Conference ([@b15]; [@b43]).

Statistically, available data suggest that the risk of myocardial infarction and sudden cardiac death during sexual intercourse, the so-called coition-induced death, is very low. Fewer than 1% of myocardial infarctions occur during sexual intercourse, and only about 0.6% of sudden cardiac deaths may be related to sexual activity ([@b51]; [@b15]; [@b29]; Ueno 2000). Nonetheless, sexual activity, even if associated with a very low absolute risk, is an established trigger of myocardial infarction ([@b15]). A 50-year-old man in the US is considered to have a baseline risk of myocardial infarction of 1.00% per year. This risk increases to 1.01% as a consequence of sexual activity. For patients with prior myocardial infarction, the risk may increase to 1.10%. Using cross-over statistics, [@b51] estimated the relative risk of myocardial infarction occurring during and within a 2-hour period after sexual intercourse as being 2.5 in comparison with non-sexual activities. Importantly, the relative risk in patients with known cardiac disease was 2.1. Interestingly, regular physical activity and cardiovascular risk factor modification might further reduce the risk ([@b73]; [@b14]). Patients with ischemic heart disease who have undergone successful revascularization (percutaneous transluminal angioplasty or coronary artery bypass surgery) are not at increased risk of myocardial infarction during sexual intercourse compared with the general population ([@b28]).

In general, physical activity is regarded as a trigger of cardiac events in susceptible patients ([@b52]). With respect to the cardiovascular system, sexual intercourse can be regarded as physical activity resulting in increased blood pressure and heart rate, which is not decisively different from other physical exercise in daily life.

While energy expenditures during sexual intercourse may vary depending on many individual factors, estimates were obtained in a laboratory setting by [@b6] using the metabolic equivalent of energy expenditure (MET) in the resting state (equal to 3.5 mL/kg/min oxygen consumption) as a quantitative parameter. Healthy males attained 2.5--3.3 METs during sexual stimulation and orgasm with some variability (2.0--5.4 METs). For comparison with daily life activities, one might say that 3 METs equals briskly climbing two flights of stairs, and 5 METs may be compared with digging in the garden. Peak heart rate during sexual intercourse ranged between 110 and 127 beats/minutes in these individuals ([@b6]). In these investigations, heart rate rarely increased to more than 130/min and systolic blood pressure rarely exceeded 170 mmHg in healthy individuals ([@b6]; [@b15]).

A possible conclusion derived from these measurements might be that a patient, who is able to achieve 5--6 METs on exercise testing without signs of ischemia, major arrhythmia or inadequate increase of blood pressure, may not be at excess risk for a cardiac event during sexual activity. In addition, effort-induced triggering of myocardial infarction is, in general, believed to be reduced by revascularization and optimized medical treatment using aspirin, β-blockers and lipid-lowering strategies ([@b27], [@b29]).

Antihypertensive interventions: cause or cure of erectile dysfunction?
======================================================================

The close association between hypertension and other cardiovascular risk factors and the presence of ED respectively and also the similarities in pathophysiology might suggest that adequate treatment of hypertension and other risk factors could favorably influence the severity or progression of ED or even result in reversal of symptoms. To the contrary, however, many antihypertensive drugs might even worsen sexual function as a drug specific side-effect, which could significantly decrease patient adherence to anti-hypertensive treatment, further increasing risk of cardiovascular morbidity. This might be true, in particular, if the question of sexual health is not openly addressed between the patient and the clinician.

Epidemiological data suggest that cessation of tobacco use can in part reverse ED ([@b49]). For diabetes mellitus, better glycemic control, measured as lower levels of glycosylated hemoglobin is associated with less severity and lower incidence of ED ([@b67]). But for hypertension, such clear data is not consistently available: Possibly two confounding factors, drug-specific side effects and beneficial effects of effective blood pressure control may make it difficult or impossible to tell whether treatment of hypertension can attenuate ED.

In general, one might consider lifestyle changes and/or medical treatment as a potential therapeutic strategy. It is quite well established that lifestyle changes associated with reduced arterial blood pressure, such as initiation of physical activity and weight loss, favorably influence sexual function. These lifestyle changes seem to be most effective at younger age compared with older patients ([@b17]).

There are experimental animal investigations, suggesting that medical treatment of hypertension may have the potential to reduce the incidence of ED ([@b26]). However, most medical antihypertensive interventions, such as thiazides, β-blocking agents etc, were reported to potentially worsen sexual function.

An exception to this rule is the experience with angiotensin II receptor type-1 blockers ([@b46]), which seem to slightly improve sexual function along with effective blood pressure control. For losartan and valsartan, clinical studies demonstrated a reduction in the incidence of ED and a slight, but consistent improvement in common parameters of erectile function ([@b21]; [@b18]). Moreover, animal studies supported the concept of improved sexual function along with effective blood pressure control under the influence of losartan ([@b76]; [@b60]).

When choosing the appropriate antihypertensive regime, one should also bear in mind that, for example, thiazide diuretics are reported to have a higher incidence of ED than β-blocking agents, the most commonly mentioned drugs in this context ([Table 3](#tbl3){ref-type="table"}). In addition, a simple weight loss diet may reverse sexual dysfunction induced by thiazide diuretics ([@b44]). Loop diuretics might be a better choice than thiazides and angiotensin II receptor type-1 blocker may have some benefit compared with angiotensin converting enzyme inhibitors ([@b10]). Calcium channel antagonists do not appear to have a high incidence of ED albeit in some cases prolactin levels increase which could interfere with sexual function. In [Table 3](#tbl3){ref-type="table"} a summary of some alternatives is shown when choosing the appropriate drug regime in cardiovascular, particularly hypertensive patients.

###### 

Medical therapy, incidence of erectile dysfunction, and potential alternatives

  Drug                                                Potential alternative                                                                                         Comment
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  thiazide diuretics                                  loop diuretics                                                                                                thiazide diuretics: higher incidence of erectile dysfunction than β-blockers
  β-blockers                                          angiotensin converting enzyme inhibitors, angiotensin II receptor type-1 blockers, calcium channel blockers   prognostic benefit after myocardial infarction or in heart failure needs to be weighed against side effects
  aldosterone receptor antagonists (spironolactone)   potassium sparing diuretics or eplerenone in the treatment of congestive heart failure                        limited information
  fibrates                                            statins                                                                                                       −
  angiotensin-converting enzyme inhibitors            angiotensin II type-1 receptor blockers                                                                       angiotensin II receptor type-1 blockers may even improve sexual function

**Notes**: Some of the alternatives may not be applicable in individual patients

Compiled according to [@b44], [@b10], [@b46], [@b62], [@b66], [@b69], and [@b9].

Interaction between treatment of erectile dysfunction and treatment of hypertension
===================================================================================

Phosphodiesterase 5 inhibitors and arterial blood pressure
----------------------------------------------------------

As mentioned above, phosphodiesterase 5 inhibitors, such as sildenafil, vardenafil and tadalafil, inhibit the breakdown of cGMP in tissues with significant phosphodiesterase 5 activity, eg, the penile vasculature, resulting in enhanced erections.

Phosphodiesterase 5 is also expressed in systemic vascular smooth muscle cells including the arterial, venous, pulmonary and coronary network; bronchial smooth muscle cells; platelets and the central nervous system ([@b81]). Looking at the mechanism of action, one could imagine that administration of phosphodiesterase 5 inhibitors, intended to treat ED, could also alter vascular hemodynamics, lower blood pressure or affect the coronary circulation. This might be of special interest in hypertensive patients or patients on various antihypertensive drugs. However, in general, blood pressure lowering effects of the three phosphodiesterase 5 inhibitors do not appear to be a major problem. Oral administration of sildenafil reduced systolic and diastolic blood pressure by 7--10 mmHg in a non-dose dependent manner ([@b84]) without any evidence of significant reflex tachycardia. Similarly, effects of sildenafil on blood pressure in hypertensive patients on multiple antihypertensive drugs (angiotensin converting enzyme inhibitors, β-adrenoceptor blockers, calcium channel antagonists) were minimal and well-tolerated ([@b82]; [@b36]; [@b79]). Comparable results were obtained with newer phosphodiesterase 5 inhibitors vardenafil and tadalafil ([@b38], b; [@b61]; [@b41]). A statistical evaluation of side-effects of sildenfil after its approval did not demonstrate an increased cardiovascular risk as compared with an adequate reference population ([@b83]). However, there are a few, but important exceptions to mention: NO donors, which have a marked blood pressure lowering effect, even if most of them are not used as antihypertensive agents, and α-adrenoceptor blocker, used as antihypertensives and in the treatment of prostate hyperplasia. Patients treated with phosphodiesterase 5 inhibitors must be informed about these interactions.

Interaction of phosphodiesterase 5 inhibitor with antihypertensive treatment
============================================================================

Nitric oxide donors
-------------------

Looking at the mechanism of vasodilation induced by phosphodiesterase 5 inhibitors, it becomes clear that the amount of preactivation of the guanylate cyclase---NO system may determine the degree of blood pressure lowering in response to phosphodiesterase 5 inhibitors ([@b12]; [@b82]). Therefore, phosphodiesterase 5 inhibitors in combination with any drug serving as a NO donor can lead to life-threatening hypotension, as uncontrolled accumulation of cGMP within the vascular smooth muscle cells can occur. 24 hours, equal to 6 half-lives of sildenafil, should elapse between administration of a nitrate and sildenfil or vice-versa ([@b12]). For vardenafil, with a similar half-life as sildenafil, also 24 hours are required until nitrate oxide donors can be used safely. For tadalafil, however, with a half-life of 17.5 hours, recent studies suggest that at least 48 hours shouldelapse after the intake of 20 mg tadalafil before nitrates can be administerd ([@b8]; [@b13]; [@b19]; [@b37]; [@b37]; [@b55]). If a patient, who has taken phosphodiesterase 5 inhibitors inadvertently receives nitrates and a marked drop in blood pressure occurs, emergency measures may range from Trendelenburg-position, aggressive fluid resuscitation to intravenous application of adrenergic drugs, or even intra-aortic balloon counterpulsation ([@b12]).

Alpha-adrenoceptor blockers
---------------------------

Another class of drugs used for treatment of hypertension requires special attention: α-adrenoceptor blockers, such as doxazosin and terazosin (used for both arterial hypertension and benign prostatic hypertrophy) and tamsulosin (an α~1a~-adrenoceptor blocker used in the treatment of prostatic hyperplasia). When vardenafil was first released to the market, it was contraindicated in combination with any α-adrenoceptor blocker as significant hypotension had been observed in some of the initial studies. This appeared also to be the case for tadalafil in combination with non-selective α~1~-adrenoceptor blockers (not for tamsulosin). Analysis of subsequent studies, however, suggested that hypotension with these combinations is less significant than initially assumed; and therefore the label "precaution" is now officially used for the combined use of PDE 5 inhibitors and α-adrenoceptor blockers ([@b1]; [@b41]).

As a rule of thumb, a baseline blood pressure of more than 90/60 mmHg is a prerequisite for any PDE 5 inhibitor to be administered. Furthermore, α-adrenoceptor blockers should only be used in combination with PDE 5 inhibitors if other alternatives do not appear to be applicable and only under close medical monitoring.

Summary
=======

In many forms of ED, cardiovascular risk factors, in particular arterial hypertension, seem to be extremely common. While causes for ED are related to a broad spectrum of diseases, a generalized vascular process seems to be the underlying mechanism in many patients, which frequently involves endothelial dysfunction, ie, inadequate vasodilation in response to endothelium-dependent stimuli, both in the systemic vasculature and the penile arteries. Due to this close association of cardiovascular disease and ED, patients with ED should be evaluated for cardiovascular risk factors including hypertension, cardiovascular disease or silent myocardial ischemia. Cardiovascular patients, seeking treatment of ED must be closely examined to determine whether treatment of ED or sexual activity can be recommended without significantly increased cardiac risk according to the guidelines issued from the Princeton Consensus Conference.

While consequent treatment of cardiovascular risk factors should be accomplished in these patients, many antihypertensive drugs may worsen sexual function as a drug specific side-effect. Effective treatment for arterial hypertension should not be discontinued as this, in the long term, most likely deteriorates sexual function. Alternative antihypertensive regimes should be administered with individually tailored drug regimes with minimal side effects on sexual function. Angiotensin II receptor type-1 blockers may be associated with little side-effects or even with a slight improvement of sexual function.
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